Aurum Biosciences

Glasgow, United Kingdom Founded: 2015 • Age: 11 yrs
Novel oxygen carriers and MRI software for stroke are developed.
Annual revenue - Latest available
Total funding $6.3M 3 rounds
Employees 6 Tracked headcount
Investors 8 Known backers
Products 2 Services tracked
Competitors 10 Brand Intelligence

About Aurum Biosciences

Aurum Biosciences is a company based in Glasgow (United Kingdom) founded in 2015. Aurum Biosciences has raised $6.3 million across 3 funding rounds from investors including Scottish Enterprise, Infinion BioPharma and InnoScot. The company has 6 employees as of March 31, 2022. Aurum Biosciences offers products and services including ABL-101 and ABL-101 Platform. Aurum Biosciences operates in a competitive market with competitors including Basking Biosciences, Acticor Biotech, Remedy Pharmaceuticals, Alveron Pharma and ZZ Biotech, among others.

  • Headquarter Glasgow, United Kingdom
  • Employees 6 as on 31 Mar, 2022
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Aurum Biosciences Limited
  • Date of Incorporation 01 Nov, 2010
  • Jurisdiction GLASGOW, SCOTLAND
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $6.3 M (USD)

    in 3 rounds

  • Latest Funding Round
    $926.33 K (USD), Series A

    Jan 31, 2024

  • Investors
  • Employee Count
    6

    as on Mar 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Aurum Biosciences

Aurum Biosciences offers a comprehensive portfolio of products and services, including ABL-101 and ABL-101 Platform.

Product name locked
Category locked
Primary

Injectable for oxygen delivery in stroke and spinal injury treatment

Product name locked
Category locked
Locked

Platform for therapeutics and diagnostics in inflammation and oncology

People of Aurum Biosciences

Headcount 1-10
Employee Profiles 3
Board Members and Advisors 2
Employee Profiles
People
David Brennan
CEO
People
Graeme Deuchar
R&D Director
People
Govind Chavada
Executive Director

Unlock access to complete

Board Members and Advisors
people
Graham Watson
Chairperson
people
Celestine Santosh
Scientific Advisor

Unlock access to complete

Funding Insights of Aurum Biosciences

Aurum Biosciences has successfully raised a total of $6.3M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $926.33 thousand completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Aurum Biosciences

Aurum Biosciences has secured backing from 8 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Scottish Enterprise, Infinion BioPharma and InnoScot.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
Early-stage Scottish companies are supported with investment and expertise.
Locked Locked Locked
Supports healthcare innovation by assessing ideas, protecting IP, and facilitating commercial deals.
Locked Locked Locked
Business development and leadership training programs are offered to companies.
Locked Locked Locked
Premium access

Investor details for Aurum Biosciences

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Aurum Biosciences

Investments
Premium access

Investment portfolio details for Aurum Biosciences

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Aurum Biosciences

Premium access

Detailed financials for Aurum Biosciences

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Aurum Biosciences Comparisons

Aurum Biosciences Primary company
Description
Novel oxygen carriers and MRI software for stroke are develo...
Location
Glasgow, United Kingdom
Founded Year
2015
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
6
As of 2022
Premium access

Peer comparison for Aurum Biosciences

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Aurum Biosciences

Aurum Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Basking Biosciences, Acticor Biotech, Remedy Pharmaceuticals, Alveron Pharma and ZZ Biotech, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Therapeutics for ischemic stroke treatment are developed.
Locked Locked Locked
Immunotherapeutics are developed for ischemic stroke treatment using monoclonal antibodies.
Locked Locked Locked
Intravenous formulation for acute central nervous system conditions such as stroke (ischemic and hemorrhagic), traumatic brain injury.
Locked Locked Locked
Drugs for haemorrhagic stroke and intracranial haemorrhage are developed.
Locked Locked Locked
Genetically engineered proteins for stroke and brain disorders are developed.
Premium access

Detailed competitors of Aurum Biosciences

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Aurum Biosciences

Premium access

Complete news archive for Aurum Biosciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Aurum Biosciences

Aurum Biosciences was founded in 2015.

Aurum Biosciences is headquartered in Glasgow, United Kingdom. It is registered at Glasgow, Scotland, United Kingdom.

Aurum Biosciences is a funded company, having raised a total of $6.3M across 3 funding rounds to date.

As of Mar 31, 2022, the latest employee count at Aurum Biosciences is 6.

Aurum Biosciences was founded in 2015 in Glasgow, United Kingdom, as a biopharmaceutical company. Novel perfluorocarbon-based oxygen carriers, known as Oxycyte, are combined with proprietary software and MRI imaging to form the Glasgow Oxygen Level Dependent (GOLD) technology. This is advanced through preclinical development and clinical studies for acute ischaemic stroke, serving as both a diagnostic tool and therapeutic option, with potential follow-on indications.

Aurum Biosciences's top competitors include Acticor Biotech, Remedy Pharmaceuticals and Basking Biosciences.

Aurum Biosciences offers ABL-101 and ABL-101 Platform.

Aurum Biosciences has 8 investors. Key investors include Scottish Enterprise, Infinion BioPharma, InnoScot, TRICAPITAL Angels, and Celestine Santosh.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available